Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript

SA Transcripts
154.2K Followers

Q2: 2025-07-17 Earnings Summary

Insights
EPS of $1.26 beats by $0.00
 | Revenue of $11.14B (7.37% Y/Y) beats by $86.98M

Abbott Laboratories (NYSE:ABT) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET

Company Participants

Michael Comilla - Vice President of Investor Relations.
Philip P. Boudreau - CFO & Executive VP of Finance
Robert B. Ford - Chairman of the Board, President & CEO

Conference Call Participants

Adam Carl Maeder - Piper Sandler & Co., Research Division
Danielle Joy Antalffy - UBS Investment Bank, Research Division
David Harrison Roman - Goldman Sachs Group, Inc., Research Division
Joshua Thomas Jennings - TD Cowen, Research Division
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division
Marie Yoko Thibault - BTIG, LLC, Research Division
Matthew Stephan Miksic - Barclays Bank PLC, Research Division
Robert Justin Marcus - JPMorgan Chase & Co, Research Division
Travis Lee Steed - BofA Securities, Research Division
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division

Operator

Good morning, and thank you for standing by. Welcome to Abbott's Second Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and- answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.

Michael Comilla

Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; Philip Boudreau, Executive Vice President, Finance and Chief Financial Officer.

Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2025.

Abbott cautions that these forward-looking statements are subject to risks

Recommended For You

About ABT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABT